Dorn G W, Burch R M, Kochel P J, Mais D E, Halushka P V
Biochem Pharmacol. 1987 Jun 15;36(12):1913-7. doi: 10.1016/0006-2952(87)90488-6.
Platelets possess membrane receptors which mediate the aggregatory response to thromboxane A2 (TXA2) and prostaglandin H2 (PGH2). It has been observed recently that the affinities for a series of TXA2/PGH2 mimetics are decreased in crude human platelet membranes and solubilized membranes compared to intact washed platelets. The present study investigated the notion that platelets contain a substance that is released during platelet lysis that reduces the affinity of the TXA2/PGH2 receptor for agonists. The displacement of 9,11-dimethylmethano-11,12-methano-16-(3-iodo-4-hydroxyphenyl)-13, 14-dihydro-13 - aza-15 alpha beta-omega-tetranor-TXA2 ([125I]PTA-OH), a TXA2/PGH2 receptor antagonist, from its binding site in intact washed platelets by TXA2/PGH2 mimetics and antagonists was characterized in the presence or absence of the supernatant (50,000 g) obtained from sonicated platelets. In the presence of the supernatant, there was a significant (P less than 0.025) increase in the IC50 values for the TXA2/PGH2 mimetics U46619, SQ26655, and ONO11113. The increase in the IC50 for U46619 induced by the supernatant was abolished by either boiling or treating the supernatant with trypsin. The supernatant did not affect the Kd or Bmax of [125I]PTA-OH or the IC50 of the TXA2/PGH2 antagonist, SQ29548. Pretreatment of the platelets with the supernatant resulted in a significant (P less than 0.02) reduction in the aggregation response induced by U46619. Gel filtration (Sephacryl S200) of the supernatant revealed a fraction (molecular weight approximately 100,000 daltons) which significantly increased the IC50 for U46619 to displace [125I]PTA-OH from its binding site. Thus, human platelets appear to possess a protein(s) that is released into the supernatant upon sonication and inhibits the binding of TXA2/PGH2 agonists but not antagonists to their receptor. This protein may play a role in the regulation of platelet responses to the aggregatory stimuli TXA2/PGH2.
血小板具有膜受体,可介导对血栓素A2(TXA2)和前列腺素H2(PGH2)的聚集反应。最近观察到,与完整的洗涤血小板相比,粗制人血小板膜和可溶性膜中一系列TXA2/PGH2模拟物的亲和力降低。本研究探讨了血小板含有一种在血小板裂解过程中释放的物质,该物质会降低TXA2/PGH2受体对激动剂的亲和力这一观点。在存在或不存在超声处理血小板获得的上清液(50,000g)的情况下,对TXA2/PGH2模拟物和拮抗剂从其在完整洗涤血小板中的结合位点置换9,11-二甲基甲撑-11,12-甲撑-16-(3-碘-4-羟基苯基)-13,14-二氢-13 -氮杂-15αβ-ω-四去甲-TXA2([125I]PTA-OH)(一种TXA2/PGH2受体拮抗剂)进行了表征。在上清液存在的情况下,TXA2/PGH2模拟物U46619、SQ26655和ONO11113的IC50值显著(P小于0.025)增加。上清液诱导的U46619的IC50增加可通过煮沸或用胰蛋白酶处理上清液而消除。上清液不影响[125I]PTA-OH的Kd或Bmax或TXA2/PGH2拮抗剂SQ29548的IC50。用该上清液预处理血小板会导致U46619诱导的聚集反应显著(P小于0.02)降低。对上清液进行凝胶过滤(Sephacryl S200)显示,有一个部分(分子量约100,000道尔顿)可显著增加U46619从其结合位点置换[125I]PTA-OH的IC50。因此,人血小板似乎含有一种蛋白质,在超声处理后释放到上清液中,抑制TXA2/PGH2激动剂而非拮抗剂与其受体的结合。这种蛋白质可能在调节血小板对聚集刺激物TXA2/PGH2的反应中起作用。